Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.
Adley I LemkeHannah M BrokmeierSarah B LeungKristin C MaraGirish K MourHani M WadeiJennifer M HillMark D StegallYogish C KudvaPankaj ShahAleksandra KuklaPublished in: Clinical transplantation (2022)
SGLT2i may be a safe and effective treatment for diabetes in kidney transplant recipients. Cost is a barrier to SGLT2i therapy, and UTIs were the most frequently encountered adverse events in this cohort. More studies are needed to understand the safety profile and determine the effect of SGLT2i on diabetes-related comorbidities among kidney transplant recipients.